Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2021-003304-41-HU
EUCTR2021-003304-41-HU
Active, not recruiting
Phase 1

A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis - CatC inhibitor Phase II in bronchiectasis

Boehringer Ingelheim RCV GmbH & Co KG0 sites240 target enrollmentDecember 21, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsbronchiectasisMedDRA version: 21.0Level: PTClassification code 10006445Term: BronchiectasisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
bronchiectasis
Sponsor
Boehringer Ingelheim RCV GmbH & Co KG
Enrollment
240
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 21, 2021
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\- Male or female (not of childbearing potential) patients
  • •\- Age of patients when signing the informed consent \=18 and \=85 years.
  • •\- Clinical history consistent with bronchiectasis (cough, chronic sputum production and/or recurrent respiratory infections) and investigator confirmed diagnosis of bronchiectasis by computed tomography (CT) scan.
  • •\- History of pulmonary exacerbations requiring antibiotic treatment. In the 12 months before Visit 1, patients must have had either:
  • •\-\- at least 2 exacerbations, or
  • •\-\- at least 1 exacerbation and a SGRQ Symptoms score of \>40 at screening visit 1\.
  • •For patients on stable oral or inhaled antibiotics as chronic treatment for bronchiectasis, at least one exacerbation must have occurred since initiation of stable antibiotics.
  • •\- Current sputum producers with a history of chronic expectoration
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:

Exclusion Criteria

  • •\- AST and / or ALT \>3\.0 x ULN at Visit 1
  • •\- Estimated glomerular filtration rate (eGFR) according to CKD\-EPI formula \< 30 mL/min at Visit 1\.
  • •\- An absolute blood neutrophil count \<1,000/mm3 at Visit 1\.
  • •\- Any clinically relevant finding in the medical examination (including BP, PR, or ECG) and/or laboratory value assessed by the Investigator at Screening Visit 1 or during screening period.
  • •\- Positive serological tests for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection, or known infection status.
  • •\- A current diagnosis of
  • •\-\- Cystic Fibrosis
  • •\-\- Hypogammaglobulinemia
  • •\-\- Common variable immunodeficiency
  • •\-\- a1\-antitrypsin deficiency

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe Restless Legs Syndrome. - ND
EUCTR2005-005372-32-ITGLAXO SMITHKLINE400
Active, not recruiting
Phase 1
A randomised, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of two doses of ketoprofen (as lysinate) lozenges (6.25mg and 12.5mg ) in patients with sore throat” - KRYSTAupper respiratory illness : sore throatMedDRA version: 9.1Level: LLTClassification code 10041367Term: Sore throat
EUCTR2008-008265-36-FRSANOFI-AVENTIS GROUPE835
Active, not recruiting
Phase 1
The effect of Tiotropium+olodaterol fixed dose combination on exercise endurance time during constant work load cycle test in patients with COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2011-004253-11-GBBoehringer Ingelheim Limited544
Active, not recruiting
Not Applicable
A randomised, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of two doses of ketoprofen lysinate lozenges (6.25mg and 12.5mg ) in patients with sore throat” - KRYSTA
EUCTR2008-008265-36-FISANOFI-AVENTIS GROUPE835
Active, not recruiting
Not Applicable
Efficacy and safety of 2 doses of Tiotropium Respimat compared to placebo in adolescents with severe persistent asthmapatients of either sex, 12 to 17 years old, with a diagnosis of severe persistent asthmaMedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2010-021778-13-DEBoehringer Ingelheim Pharma GmbH & Co. KG375